LTS is the market leader in transdermal therapeutic systems and oral thin films. We develop and manufacture innovative drug delivery systems that offer the patient reliable therapeutic efficacy with the highest level of convenience and comfort – the benefits of which have already proven themselves on the global markets.

LTS Executive Board

The team of the Executive Board shapes the future of LTS as market leader for transdermal innovative solutions.
Some of the most important tasks of the LTS Executive Board are the development of corporate strategy, the fixing of the company budged as well as the allocation of resources. It informs the Supervisory Board on a regular basis in a timely and comprehensive manner about all questions relevant to LTS AG, e.g., planning, corporate development, risk analyses and risk management.


Learn more about …

The Team of the LTS Executive Board

LTS Supervisory Board

The Supervisory Board of LTS monitors and consults with the Executive Board. It consists of six members.

Prof. Dr. Christof Hettich (Chairman of the Supervisory Board)
Dr. Jochen Wolf
Oliver Hopp
Rüdiger Busley
Erika Weiler
Michael Mildner

The composition of the Supervisory Board is determined by the “One-third Co-Determination Law (DrittelBG)”. Accordingly, two-thirds or four members of the Supervisory Board are appointed by the shareholders and one-third or two Supervisory Board members by the employees. The Supervisory Board is directly involved in decisions of a fundamental nature for the company. Further, the Supervisory Board also synchronizes the strategic direction of the company with the Executive Board and discusses the status of implementation of the corporate strategy with the Executive Board on a regular basis.

Learn more about …